Anti-Human PD-L1 (Atezolizumab) [RG7446] — DyLight® 488
Anti-Human PD-L1 (Atezolizumab) [RG7446] — DyLight® 488
Product No.: LT1753
Product No.LT1753 Clone RG7446 Target PD-L1 Product Type Biosimilar Recombinant Human Monoclonal Antibody Alternate Names Programmed Death Ligand 1, B7-H1, PD-L1, CD274 Isotype Human IgG Applications FC , WB |
Antibody DetailsProduct DetailsReactive Species Human Host Species Human Expression Host HEK-293 Cells Immunogen Unknown Product Concentration 0.2 mg/ml Formulation This DyLight® 488 conjugate is formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.4, 1% BSA and 0.09% sodium azide as a preservative. Pathogen Testing To protect mouse colonies from infection by pathogens and to assure that experimental preclinical data is not affected by such pathogens, all of Leinco’s recombinant biosimilar antibodies are tested and guaranteed to be negative for all pathogens in the IDEXX IMPACT I Mouse Profile. Storage and Handling Functional grade preclinical antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at ≤ -70°C. Avoid Repeated Freeze Thaw Cycles. Regulatory Status Research Use Only (RUO). Non-Therapeutic. Country of Origin USA Shipping Next Day 2-8°C Excitation Laser Blue Laser (493 nm) Applications and Recommended Usage? Quality Tested by Leinco FC The suggested concentration for Atezolizumab biosimilar antibody for staining cells in flow cytometry is ≤ 0.25 μg per 106 cells in a volume of 100 μl. Titration of the reagent is recommended for optimal performance for each application. Additional Applications Reported In Literature ? WB Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change. DescriptionDescriptionSpecificity This non-therapeutic biosimilar antibody uses the same variable region sequence as the therapeutic antibody Atezolizumab. Atezolizumab recognizes an epitope on mouse PD-L1. This product is for research use only. Background PD-1 is a 50-55 kD member of the B7 Ig superfamily. PD-1 is also a member of the extended CD28/CTLA-4 family of T cell regulators and is suspected to play a role in lymphocyte clonal selection and peripheral tolerance. The ligands of PD-1 are PD-L1 and PD-L2, and are also members of the B7 Ig superfamily. PD-1 and its ligands negatively regulate immune responses. PD-L1, or B7-Homolog 1, is a 40 kD type I transmembrane protein that has been reported to costimulate T cell growth and cytokine production. The interaction of PD-1 with its ligand PD-L1 is critical in the inhibition of T cell responses that include T cell proliferation and cytokine production. PD-L1 has increased expression in several cancers. Inhibition of the interaction between PD-1 and PD-L1 can serve as an immune checkpoint blockade by improving T-cell responses In vitro and mediating preclinical antitumor activity. Within the field of checkpoint inhibition, combination therapy using anti-PD1 in conjunction with anti-CTLA4 has significant therapeutic potential for tumor treatments. PD-L2 is a 25 kD type I transmembrane ligand of PD-1. Via PD-1, PD-L2 can serve as a coinhibitor of T cell functions. Regulation of T cell responses, including enhanced T cell proliferation and cytokine production, can result from mAbs that block the PD-L2 and PD-1 interaction. Antigen Distribution PD-L1 is present on T cells, B cells, NK cells, dendritic cells, IFN-γ activated endothelial cells, and monocytes. Ligand/Receptor PD-1 (PDCD1) Research Area Biosimilars . Cancer . Costimulatory Molecules . Immunology Leinco Antibody AdvisorPowered by AI: AI is experimental and still learning how to provide the best assistance. It may occasionally generate incorrect or incomplete responses. Please do not rely solely on its recommendations when making purchasing decisions or designing experiments. Research-grade Atezolizumab biosimilars are used as calibration standards or reference controls in pharmacokinetic (PK) bridging ELISA by serving as the quantifiable basis for standard curves against which unknown serum concentrations are measured. These biosimilar standards are carefully validated to match the reference (originator) drug, ensuring assay precision, accuracy, and comparability across batches and laboratories. Key details on their use:
In summary, a research-grade Atezolizumab biosimilar is used as the quantifiable reference in the ELISA calibration curve, QC controls, and method validation process, enabling accurate, equivalent measurement of both biosimilar and reference drug concentrations in serum for regulatory pharmacokinetic bridging studies. Standard flow cytometry protocols using a conjugated Atezolizumab biosimilar (e.g., PE- or APC-labeled) to validate PD-L1 expression or binding capacity generally involve direct staining of cells expressing PD-L1, titration of the antibody, and analysis of fluorescence intensity to quantify surface PD-L1 levels or binding affinity. This approach is suitable for both cell line validation and, in some contexts, patient or preclinical samples. Essential Protocol Steps and Key Points
Example – Use Case and ReportingA study evaluating the binding of Atezolizumab to PD-L1-expressing cells by flow cytometry serially titrated the antibody, stained cells, and detected the bound antibody using an APC-conjugated anti-human IgG secondary (in the absence of a directly labeled antibody, but this is analogous to the use of direct conjugates). The mean fluorescence intensity correlates with available surface PD-L1, and binding curves are used to calculate affinity parameters such as EC50. Commercial sources provide APC-conjugated Atezolizumab biosimilar for research specifically validated for flow cytometry and recommend titration to optimize staining for the precise sample type. Additional Considerations
In summary: The standard protocol is: label cells with titrated direct Atezolizumab-conjugate, incubate, wash, and analyze by flow cytometry, using controls to establish background and specificity. This method robustly validates PD-L1 expression levels and antibody binding capacity on various cell types. Biopharma companies typically perform a comprehensive set of analytical assays to confirm the structural and functional similarity of a proposed biosimilar to the originator drug, using validated and highly sensitive techniques to examine both structural features and biological activity. Core Analytical Assays for Biosimilar Characterization
Regulatory and Scientific Context
About Leinco Biosimilars While the search results do not explicitly mention Leinco’s specific use in biosimilar similarity studies, Leinco Technologies is known in the life science industry for providing reference standards and well-characterized biosimilar antibodies that serve as benchmarks in analytical method development and comparability exercises. In biosimilar analytical studies, a “Leinco biosimilar” could be used as either:
In summary, biopharma companies rely on a battery of structural and functional assays, including peptide mapping, higher-order structure analyses, impurity profiling, binding, and potency assays, conducted in a comparative, head-to-head manner—often making use of high-quality standards or biosimilars like those provided by Leinco for reference or assay development purposes. References & Citations1. Ardolino, M. et al. (2018) J Clin Invest. 128(10):4654-4668. PubMed 2. Schreiber, RD. et al. (2017) Cancer Immunol Res. 5(2):106-117. 3. Freeman, G. et al. (2000) J. Exp. Med. 192:1027. Technical ProtocolsCertificate of Analysis |
Formats Available
